miR-486-5p expression pattern in esophageal squamous cell carcinoma, gastric cancer and its prognostic value

Micro RNA (miR)-486-5p is often aberrantly expressed in human cancers. The aim of this study was to identify the prognostic value of miR-486-5p expression in digestive system cancers. Tissue microarrays were constructed with 680 samples including 185 esophageal squamous cell carcinomas (ESCCs), 90 gastric adenocarcinomas (GCs), and 60 digestive system cancer tissues from 10 ESCC, 10 GC, 10 colon, 10 rectum, 10 liver, 10 pancreatic cancer, and corresponding normal tissues. Twenty normal digestive system mucosa tissues from healthy volunteers were included as normal controls. In GC, miR-486-5p expression was decreased in 62.8% of cases (59/94), increased in 33.0% (31/94), and unchanged in 4.2% (4/94); in ESCC its expression was decreased in 66.2% (129/195), increased in 32.3% (63/195), and unchanged in 1.5% (3/195). Expression of miR-486-5p was decreased in 12, and increased in 8, of 20 cases of colon or rectum cancer; decreased in 6, and increased in 4, of 10 cases of liver cancer; and decreased in 8, and increased in 2, of 10 cases of pancreatic cancer. Multivariate and univariate regression analysis demonstrated that low/unchanged miR-486-5p predicted poor prognosis in ESCC (hazard ratio [HR], 4.32; 95% confidence interval [CI], 2.62–7.14; P < 0.001; HR, 3.88; 95% CI, 2.43–6.22; P < 0.001, respectively) and GC (HR, 2.46; 95% CI, 1.35–4.50; P = 0.003; HR, 2.55; 95% CI, 1.39–4.69; P = 0.002, respectively). MiR-486-5p might therefore be an independent tumor marker for evaluating prognosis in patients with ESCC or GC.

[1]  Xiaofei Zheng,et al.  miR‐486 regulates metastasis and chemosensitivity in hepatocellular carcinoma by targeting CLDN10 and CITRON , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  Vivian T. Yin,et al.  Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. , 2015, JAMA ophthalmology.

[3]  Xiaoping Liu,et al.  MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer , 2015, PloS one.

[4]  Mei Liu,et al.  Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy , 2015, Cancer biology & therapy.

[5]  Rui Zhang,et al.  Expression of circulating miR-486 and miR-150 in patients with acute myocardial infarction , 2015, BMC Cardiovascular Disorders.

[6]  Chuanli Ren,et al.  Expression and Prognostic Value of miR-486-5p in Patients with Gastric Adenocarcinoma , 2015, PloS one.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  J. Hou,et al.  MicroRNA‐486‐5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1 , 2015, The FEBS journal.

[9]  Xiaohong Wang,et al.  MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells , 2014, Tumor Biology.

[10]  Jamie L. Marshall,et al.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. , 2014, The Journal of clinical investigation.

[11]  Hongbing Shen,et al.  A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer , 2014, British Journal of Cancer.

[12]  X Wang,et al.  Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer , 2014, Oncogene.

[13]  Xiaoying Shen,et al.  Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer. , 2014, International journal of clinical and experimental pathology.

[14]  F. Sánchez‐Madrid,et al.  Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs , 2013, Nature Communications.

[15]  Li Liang,et al.  Isothermally sensitive detection of serum circulating miRNAs for lung cancer diagnosis. , 2013, Analytical chemistry.

[16]  C. Croce,et al.  Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[17]  Dongfeng Li,et al.  Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal Cancer , 2013, PloS one.

[18]  Sun Young Lee,et al.  miR-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose. , 2012, Stem cells and development.

[19]  S. Meltzer,et al.  MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. , 2012, Gastroenterology.

[20]  T Kawaguchi,et al.  Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma , 2012, British Journal of Cancer.

[21]  Fang Zhou,et al.  A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis , 2011, Clinical Cancer Research.

[22]  R. Agami,et al.  MicroRNA regulation by RNA-binding proteins and its implications for cancer , 2011, Nature Reviews Cancer.

[23]  Feng Jiang,et al.  Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers , 2011, BMC Cancer.

[24]  D. Ichikawa,et al.  Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma , 2011, British Journal of Cancer.

[25]  A. Rastogi,et al.  Feasibility of MicroRNAs as Biomarkers for Barrett's Esophagus Progression: A Pilot Cross-Sectional, Phase 2 Biomarker Study , 2011, The American Journal of Gastroenterology.

[26]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[27]  F. Basile,et al.  Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment , 2010, Molecular Cancer Therapeutics.

[28]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[29]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Olson,et al.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486 , 2010, Proceedings of the National Academy of Sciences.

[31]  Israel Steinfeld,et al.  Novel Rank-Based Statistical Methods Reveal MicroRNAs with Differential Expression in Multiple Cancer Types , 2009, PloS one.

[32]  C. Abnet,et al.  Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China , 2005, International journal of cancer.

[33]  R. Malekzadeh,et al.  Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran , 2004, British Journal of Cancer.

[34]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[35]  Z. Yakhini,et al.  Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. , 2014, Carcinogenesis.

[36]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[37]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.